{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:43:39Z","timestamp":1762375419000},"reference-count":27,"publisher":"Japanese Society of Allergology","issue":"2","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T00:00:00Z","timestamp":1430265600000},"content-version":"vor","delay-in-days":1944,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2010]]},"DOI":"10.2332\/allergolint.09-oa-0137","type":"journal-article","created":{"date-parts":[[2010,6,28]],"date-time":"2010-06-28T06:06:21Z","timestamp":1277705181000},"page":"167-174","source":"Crossref","is-referenced-by-count":17,"title":["One Year Treatment with Omalizumab Is Effective and Well Tolerated in Japanese Patients with Moderate-to-Severe Persistent Asthma"],"prefix":"10.2332","volume":"59","author":[{"given":"Ohta","family":"Ken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimitoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terumasa","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1154","reference":[{"key":"10.2332\/allergolint.09-OA-0137_bb0005","first-page":"548","article-title":"The public health implications of asthma","volume":"83","author":"Bousquet","year":"2005","journal-title":"Bull World Health Organ"},{"key":"10.2332\/allergolint.09-OA-0137_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.02.00232001","article-title":"Costs of asthma are correlated with severity: a 1-yr prospective study","volume":"19","author":"Godard","year":"2002","journal-title":"Eur Respir J"},{"key":"10.2332\/allergolint.09-OA-0137_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1081-1206(10)61707-3","article-title":"Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma","volume":"92","author":"Dolan","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3109\/02770909809048968","article-title":"Features that distinguish those who die from asthma from community controls with asthma","volume":"35","author":"Tough","year":"1998","journal-title":"J Asthma"},{"key":"10.2332\/allergolint.09-OA-0137_bb0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1183\/09031936.04.00064204","article-title":"Relationship between quality of life and clinical status in asthma: a factor analysis","volume":"23","author":"Juniper","year":"2004","journal-title":"Eur Respir J"},{"issue":"Suppl 2","key":"10.2332\/allergolint.09-OA-0137_bb0030","first-page":"21","article-title":"The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study","volume":"60","author":"Turk","year":"2005","journal-title":"Thorax"},{"key":"10.2332\/allergolint.09-OA-0137_bb0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaci.2004.04.042","article-title":"Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys","volume":"114","author":"Rabe","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2466-6-13","article-title":"Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study","volume":"6","author":"Partridge","year":"2006","journal-title":"BMC Pulm Med"},{"key":"10.2332\/allergolint.09-OA-0137_bb0045","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jaci.2007.03.022","article-title":"Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey","volume":"119","author":"Peters","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0050","series-title":"Annual population survey report from the Ministry of Health","year":"2007"},{"key":"10.2332\/allergolint.09-OA-0137_bb0055","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta","year":"1993","journal-title":"J Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000237010","article-title":"Inhibition of allergic reactions with antibody to IgE","volume":"107","author":"Shields","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.2332\/allergolint.09-OA-0137_bb0070","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1398-9995.2004.00533.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma","volume":"59","author":"Ayres","year":"2004","journal-title":"Allergy"},{"key":"10.2332\/allergolint.09-OA-0137_bb0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"key":"10.2332\/allergolint.09-OA-0137_bb0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1081-1206(10)62170-9","article-title":"Omalizumab is effective in the long-term control of severe allergic asthma","volume":"91","author":"Lanier","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0090","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"10.2332\/allergolint.09-OA-0137_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1183\/09031936.02.00278102","article-title":"Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma","volume":"20","author":"Buhl","year":"2002","journal-title":"Eur Respir J"},{"key":"10.2332\/allergolint.09-OA-0137_bb0100","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.2332\/allergolint.09-OA-0137_bb0105","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1843.2009.01633.x","article-title":"Efficacy and safety of omalizumab in an Asian population with moderate to severe persistent asthma","volume":"14","author":"Ohta","year":"2009","journal-title":"Respirology"},{"issue":"Suppl 1","key":"10.2332\/allergolint.09-OA-0137_bb0110","first-page":"1","article-title":"Asthma Prevention and Management Guidelines","volume":"121","author":"Ministry of Health and Welfare, Japan","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0115","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH Publication No 023659. Revised 2007. Available at: http:\/\/www.ginasthma.org Accessed May 15, 2009."},{"key":"10.2332\/allergolint.09-OA-0137_bb0120","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMct055184","article-title":"Omalizumab for asthma","volume":"354","author":"Strunk","year":"2006","journal-title":"N Engl J Med"},{"key":"10.2332\/allergolint.09-OA-0137_bb0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis","volume":"106","author":"\u00c4delroth","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(97)70202-1","article-title":"Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis","volume":"100","author":"Casale","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.2332\/allergolint.09-OA-0137_bb0135","unstructured":"National Asthma Education and Prevention Program. Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. Available at: http:\/\/www.nhlbi.nih.gov\/guidelines\/asthma Accessed May 15, 2009."}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1323893015305888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1323893015305888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T21:04:47Z","timestamp":1711573487000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893015305888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"alternative-id":["S1323893015305888"],"URL":"https:\/\/doi.org\/10.2332\/allergolint.09-oa-0137","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}